Arbortristoside A
Arbortristoside A is an orally active inhibitor of prostaglandin (prostaglandin), histamine (histamine) and serotonin (serotonin). Arbortristoside A mediates anti-inflammatory, analgesic, anti-allergic, immunomodulatory, antiviral and anti-ulcerogenic effects, and also exhibits in vitro anticancer activity. Arbortristoside A can be used in research related to human hepatocellular carcinoma, breast cancer, fibrosarcoma, leishmaniasis, allergic diseases, viral infections and gastric ulcers.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 97145-52-3
- Formel: C27H34O13
- Molecular Weight:566.55
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle Histamine Receptor Isoform-spezifische Produkte anzeigen
MoreAlle 5-HT Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
In Vitro
Arbortristoside A (compound AT) at concentrations of 30-100 μg/mL exhibits potent antileishmanial activity against Leishmania donovani amastigotes in vitro[3].
Arbortristoside A exhibits antiviral activity against encephalomyocarditis virus and Semliki Forest virus in vitro[3].
Arbortristoside A (0-125 μg/mL; 10 min pre-incubation, 20 min assay incubation) inhibits H+K+-ATPase activity in rat gastric microsomes, with an IC50 of 103.86 μg/mL[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Arbortristoside-A (50-75 mg/kg; i.p.; single administration) dose-dependently inhibits acetic acid (HY-Y0319)-induced writhing response in Swiss albino mice[1].
Arbortristoside-A (50-75 mg/kg; i.p.; single administration) dose-dependently prolongs the pain response time of Swiss albino mice tested by the Eddy hot-plate method[1].
Arbortristoside A (10-40 mg/kg; p.o.; single administration) dose-dependently protects rats against cold restraint stress-induced gastric ulcers[4].
Arbortristoside A (20 mg/kg; p.o.; single dose) exerts a significant protective effect against ethanol-induced gastric ulcers in rats[4].
Arbortristoside A (20 mg/kg; p.o.; single administration) exerts a 48.45% protective effect against Aspirin (HY-14654)-induced gastric ulcers in rats[4].
Arbortristoside A (20 mg/kg; p.o.; single administration) exerts a 50.0% protective effect against pylorus ligation-induced gastric ulcers in rats, while reducing gastric acid secretion and increasing mucin production[4].
Arbortristoside A (20 mg/kg; p.o.; once daily; for 10 consecutive days) increases the healing rate of acetic acid-induced chronic gastric ulcers in rats to 55.94%[4].
Arbortristoside A (2.5 mg/kg) exhibits anticancer activity in methylcholanthrene-induced fibrosarcoma mice[3].
Arbortristoside A (5 mg/kg; i.g.; single dose) exhibits immunomodulatory activity in mice, protects against systemic Candida albicans infection and enhances immune responses[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar albino (weighing 150-180 g)[1]
-
Dosage:50, 75 mg/kg
-
Administration:i.p.; single dose
-
Result:Reduced paw edema.
-
Animal Model:Swiss albino (weighing 18-22 g)[1]
-
Dosage:50, 75 mg/kg
-
Administration:i.p.; single dose
-
Result:Reduced Acetic acid-induced writhing counts.
-
Animal Model:Swiss albino (weighing 18-22 g; fasted for 12 hours with access to water)[1]
-
Dosage:50, 75 mg/kg
-
Administration:i.p.; single dose
-
Result:Increased pain reaction time.
-
Animal Model:Sprague-Dawley (adult female, 180-220 g, chronic acetic acid-induced)[4]
-
Dosage:20 mg/kg
-
Administration:p.o.; daily; 10 days
-
Result:Provided 55.94% ulcer healing compared to controls.
Increased gastric mucosal PGE2 levels to 3857 pg/mg protein from control level of 2551 pg/mg protein.
Restored mucosal epithelium, reduced inflammatory exudates, and improved glandular organization based on histopathology.
Suppressed ulcer-induced increase in TNF-α and IL-1β mRNA expression.
Left COX-1 expression unchanged relative to sham and control groups.
Chemical Information
-
CAS. Nr. 97145-52-3
-
Molecular Weight 566.55
-
Formel C27H34O13
-
SMILES
COC(C=C1)=CC=C1/C=C/C(O[C@H]2[C@@]3([H])[C@]([C@H]([C@H]2O)C)([H])[C@@H](OC=C3C(OC)=O)O[C@@H]4O[C@@H]([C@H]([C@@H]([C@H]4O)O)O)CO)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)